Literature DB >> 10605005

CD28 costimulation mediates T cell expansion via IL-2-independent and IL-2-dependent regulation of cell cycle progression.

L J Appleman1, A Berezovskaya, I Grass, V A Boussiotis.   

Abstract

In the presence of TCR ligation by Ag, CD28 pathway mediates the most potent costimulatory signal for T cell activation, cytokine secretion, and T cell expansion. Although CD28 costimulation promotes T cell expansion due to IL-2 secretion and subsequent signaling via the IL-2 receptor, recent studies indicate that the dramatic T cell expansion mediated through the unopposed CD28 stimulation in CTLA4-deficient mice is IL-2 independent. Therefore, we sought to dissect the effects of CD28 and IL-2 receptor pathways on cell cycle progression and determine the molecular mechanisms by which the CD28 pathway regulates T cell expansion. Here we show that CD28 costimulation directly regulates T cell cycle entry and progression through the G1 phase in an IL-2-independent manner resulting in activation of cyclin D2-associated cdk4/cdk6 and cyclin E-associated cdk2. Subsequent progression into the S phase is mediated via both IL-2-dependent and IL-2-independent mechanisms and, although in the absence of IL-2 the majority of T cells are arrested at the G1/S transition, a significant fraction of them progresses into the S phase. The key regulatory mechanism for the activation of cyclin-cdk complexes and cell cycle progression is the down-regulation of p27kip1 cdk inhibitor, which is mediated at the posttranscriptional level by its ubiquitin-dependent degradation in the proteasome pathway. Therefore, CD28 costimulation mediates T cell expansion in an IL-2-independent and IL-2 dependent manner and regulates cell cycle progression at two distinct points: at the early G1 phase and at the G1/S transition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605005     DOI: 10.4049/jimmunol.164.1.144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

1.  Abrogating Cbl-b in effector CD8(+) T cells improves the efficacy of adoptive therapy of leukemia in mice.

Authors:  Ingunn M Stromnes; Joseph N Blattman; Xiaoxia Tan; Sara Jeevanjee; Hua Gu; Philip D Greenberg
Journal:  J Clin Invest       Date:  2010-09-20       Impact factor: 14.808

Review 2.  mTOR at the crossroads of T cell proliferation and tolerance.

Authors:  Anna Mondino; Daniel L Mueller
Journal:  Semin Immunol       Date:  2007-03-23       Impact factor: 11.130

3.  IL-2 signaling prevents T cell anergy by inhibiting the expression of anergy-inducing genes.

Authors:  Myrianne Duré; Fernando Macian
Journal:  Mol Immunol       Date:  2008-11-05       Impact factor: 4.407

4.  CD27 sustains survival of CTLs in virus-infected nonlymphoid tissue in mice by inducing autocrine IL-2 production.

Authors:  Victor Peperzak; Yanling Xiao; Elise A M Veraar; Jannie Borst
Journal:  J Clin Invest       Date:  2009-12-01       Impact factor: 14.808

5.  TGFbeta1 expression in colonic mucosa: modulation by dietary lipids.

Authors:  Fiorella Biasi; Cinzia Mascia; Giuseppe Poli
Journal:  Genes Nutr       Date:  2007-09-27       Impact factor: 5.523

Review 6.  mTOR: taking cues from the immune microenvironment.

Authors:  Greg M Delgoffe; Jonathan D Powell
Journal:  Immunology       Date:  2009-08       Impact factor: 7.397

7.  Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation.

Authors:  Lindsay J Celada; Joseph E Rotsinger; Anjuli Young; Guzel Shaginurova; Debresha Shelton; Charlene Hawkins; Wonder P Drake
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

Review 8.  Biochemical signaling of PD-1 on T cells and its functional implications.

Authors:  Vassiliki A Boussiotis; Pranam Chatterjee; Lequn Li
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

9.  Regulation of alloimmune Th1 responses by the cyclin-dependent kinase inhibitor p21 following transplantation.

Authors:  Theodore H Welling; Guanyi Lu; Keri Csencsits; Sherri C Wood; Lamis Jarvinen; D Keith Bishop
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

10.  Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?

Authors:  Marna G Bouwhuis; Andreas Gast; Adina Figl; Alexander M M Eggermont; Kari Hemminki; Dirk Schadendorf; Rajiv Kumar
Journal:  Cancer Immunol Immunother       Date:  2010-02       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.